share_log

Aprea Therapeutics on Wednesday Received FDA Orphan Drug Designation for eprenetapopt for Treatment of Acute Myeloid Leukemia

Aprea Therapeutics on Wednesday Received FDA Orphan Drug Designation for eprenetapopt for Treatment of Acute Myeloid Leukemia

Aprea治療公司週三獲得FDA用於治療急性髓系白血病的Eprenetapopt孤兒藥物名稱
Benzinga Real-time News ·  2021/04/08 05:02

https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=797420

Https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=797420

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論